Targeted Immunotherapy for Prostate Cancer with PROSTVAC

/in /by

Neal D. Shore, MD, FACS, sits down with CTA to discuss PROSTVAC targeted immunotherapy for prostate cancer.

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][su_button url=”http://www.cancertherapyadvisor.com/prostvac-prostate-cancer-immunotherapy-results/article/380602/?DCMP=EMC-CTA_weekly_rd&CPN&spMailingID=9814940&spUserID=MzA3NTMwMjM2MTAS1&spJobID=420205585&spReportId=NDIwMjA1NTg1S0″ target=”blank” background=”#024458″ size=”5″]View Article[/su_button][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]